Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

September 29, 2023

Study Completion Date

November 30, 2023

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Palbociclib

"Cohort A, B1 y B2: Palbociclib oral dose of 200 mg/day for 2 weeks, followed by 1 week off.~Cohort C1: Palbociclib oral dose 125 mg/d for 3 weeks, followed by one week off, in 4-week cycles."

DRUG

Trastuzumab

Loading dose of 8mg/kg intravenous (iv) followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.

DRUG

Endocrine therapy

Non-steroidal AIs (anastrozole, letrozole); steroidal AI (exemestane); Fulvestrant or Tamoxifen

DRUG

Chemotherapy

Gemcitabine, vinorelbine, capecitabine, eribulin or a taxane

DRUG

Antibody-Drug Conjugates

3.6 mg/kg iv every 3 weeks

Trial Locations (35)

10003

Hospital San Pedro de Alcantara, Cáceres

15006

Complejo Hospitalario Universitario A Coruña, A Coruña

18014

Hospital Universitario Virgen de las Nieves, Granada

18016

HU Clínico San Cecilio, Granada

24071

Complejo Asistencial Universitario de León, León

25198

HU Arnau de Vilanova Lleida, Lleida

28933

Hospital Universitario Rey Juan Carlos, Móstoles

37007

Hospital Universitario de Salamanca, Salamanca

41009

Hospital Virgen Universitario Virgen de Macarena, Seville

41013

Hospital Quirón Salud Sagrado Corazón, Seville

46009

Instituto Valenciano de Oncología, Valencia

46014

Hospital General Universitario de Valencia, Valencia

08916

ICO-Badalona, Badalona

08195

Hospital General De Catalunya, Sant Cugat del Vallès

Unknown

Hospital General Universitario de Alicante, Alicante

Hospital Clínic de Barcelona, Barcelona

Hospital de la Santa Creu i Sant Pau, Barcelona

Hospital Universitario del Vall d' Hebron, Barcelona

ICO Hospitalet, Barcelona

Hospital de Basurto, Bilbao

Consorcio Hospitalario Provincial de Castellón, Castellon

Hospital Reina Sofía de Córdoba, Córdoba

Centro Integral Oncológico Clara Campal (CIOCC), Madrid

H. Severo Ochoa, Madrid

H. U Puerta de Hierro, Madrid

Hospital Universitario Doce de Octubre, Madrid

Hospital Universitario Ramon y Cajal, Madrid

Hospital Son Llatzer, Palma de Mallorca

Hospital Universitario Son Espases, Palma de Mallorca

Complejo Hospitalario de Navarra, Pamplona

Hospital Universitario Virgen del Rocio, Seville

Hospital Universitario Sant Joan de Reus, Tarragona

Hospital Clinico Universitario de Valencia, Valencia

Hospital Álvaro Cunqueiro, Vigo

06080

Hospital Universitario de Badajoz, Badajoz

All Listed Sponsors
lead

SOLTI Breast Cancer Research Group

OTHER

NCT02448420 - Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter